Strides, Kenox Partner for US Nasal Spray Market

Strides Pharma Science Ltd. announced that its wholly owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has formed a strategic product development partnership with Kenox Pharmaceuticals Inc.

This collaboration is intended to strengthen Strides’ portfolio of nasal spray products targeting the US market across various therapeutic areas.

Kenox, a rapidly expanding contract development and manufacturing organization that specializes in orally inhaled and nasal drug products (OINDPs), will offer formulation and development expertise to assist Strides in the creation and regulatory submission of several nasal spray products.Although specific product information has not yet been revealed, the partnership aims to expedite the availability of affordable, high-quality medications for patients in the US.

Aditya Kumar, Executive Director of Business Development at Strides Pharma Science, said, "Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain."

Also Read:  Sanofi Highlights 31 Abstracts on Inflammatory Respiratory Diseases at ERS

"Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market strengths, allowing us to accelerate our range of nasal spray offerings in the US market," he added.

Dr Sitaram Velaga, Founder, President, and CEO of Kenox Pharmaceuticals Inc., said, "Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price."